Colorectal polyp
Conditions
Interventions
Group to discontinuing DOACs for 1 day before lower endoscopy
Group to discontinue DOACs for 1 day after endoscopic resection
Sponsors
Osaka International Cancer Institute
Madowazu investigators
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1 Person > 20 , < 80 years old 2 Patients taking direct oral anticoagulants (DOACs) 3 Appropriate informed consent. 4 PS, 0 or 1. 5 Blood test data Platelet count > 100,000 Serum creatinine < 2.0mg / dl PT% > 40% 6 Follow up of 30 days after treatment. Note: Registration is possible even in cases after colorectal surgery.
Exclusion criteria
Exclusion criteria: 1 Person who has registered in this test. 2 Inflammatory bowel disease, colon polyposis. 3 Patients are receiving systemic steroids, antiplatelet drugs, and multiple anticoagulants continuously. (However, patients who can respond to antiplatelet drugs according to the guidelines of the Japanese Endoscopy Society can be registered.) 4 Blood coagulation dysfunction disease. 5 Women who are pregnant, may become pregnant, or are breastfeeding. 6 Patients with psychosis or psychiatric symptoms seem to have difficulty participating in the study. 7 Active bacterial and fungal infection (has a fever of 38.5 degrees or higher and is associated with bacterial infectivity by diagnostic imaging or bacteriological examination). 8 Uncontrolled hypertension. 9 Respiratory disease requiring continuous oxygen administration. 10 Dialysis. 11 Others who are judged inappropriate by the attending physician (eg, the prescribing physician of the anticoagulant determined that participation in this study was dangerous).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of severe bleeding (uncontrolled intraoperative and postoperative bleeding) associated with polypectomy. | — |
Secondary
| Measure | Time frame |
|---|---|
| Rate of postoperative bleeding without emergency endoscopic hemostasis after polypectomy Rate of bleeding requiring blood cessation immediately after polypectomy DOAC dose intensity ( dose intensity) The rate of bleeding in patients who underwent only Cold Snare / Forceps Polypectomy The rate of bleeding by the type of DOAC, the rate of adverse events (the rate of thromboembolism, Incidence). | — |
Countries
Japan
Contacts
Public ContactMitsuhiro Kono
Osaka International Cancer Institute Department of Gastrointestinal Oncology
Outcome results
None listed